Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons

Radiation Research

Volumn 170, Issue 2, 2008, Pages 192-200

  Pouget, Jean Pierre ^a,b   Santoro, Lore ^b   Raymond, Laure ^b   Chouin, Nicolas ^c   Bardiès, Manuel ^c   Bascoul Mollevi, Caroline ^d   Huguet, Helena ^d   Azria, David ^b   Kotzki, Pierre Olivier ^b,e   Pèlegrin, Monique ^b   Vivès, Eric ^b,e   Pèlegrin, André ^b  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c Team 12   (France)

^d CENTRE VAL D AURELLE   (France)

^e NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125;

ARTICLE; AUGER ELECTRON SPECTROSCOPY; CARCINOMA CELL; CELL MEMBRANE; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; ELECTRON RADIATION; FEMALE; HUMAN; HUMAN CELL; IONIZING RADIATION; LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY;

CARCINOMA; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG DELIVERY SYSTEMS; ELECTRONS; FEMALE; HUMANS; IODINE RADIOISOTOPES; RADIATION DOSAGE;

EID: 49249116990     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1359.1     Document Type: Article

References (40)

1. A. I. Kassis, Radiotargeting agents for cancer therapy. Expert Opin. Drug Deliv. 2, 981-991 (2005).
2. F. Buchegger, F. Perillo-Adamer, Y. M. Dupertuis and A. Bischof Delaloye, Auger radiation targeted into DNA: A therapy perspective. Eur. J. Nucl. Med. Mol. Imaging 33, 1352-1363 (2006).
3. 131iodine. Radiat. Res. 47, 94-109 (1971).
4. 125IUdR in mammalian cells: Implications of localized energy deposition by Auger processes. Radiat. Res. 109, 78-89 (1987).
5. 125I atoms not bound to DNA. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 37, 547-554 (1980).
6. 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J. Nucl. Med. 44, 1469-1478 (2003).
7. 111In-labeled trastuzumab (herceptin) modified with nuclear localization sequences (NLS): An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J. Nucl. Med. 48, 1357-1368 (2007).
8. 131I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J. Nucl. Med. 42, 1251-1256 (2001).
9. 186Re as a function of tumor size, uptake, and intracellular distribution. Int. J. Radiat. Oncol. Biol. Phys. 36, 197-204 (1996).
10. M. J. Mattes, Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer 94, 1215-1223 (2002).
11. 125I in mammalian cells. Radiat. Res. 111, 305-318 (1987).
12. T. M. Behr, M. Behe, M. Lohr, G. Sgouros, C. Angerstein, E. Wehrmann, K. Nebendahl and W. Becker, Therapeutic advantages of Auger electronover beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur. J. Nucl. Med. 27, 753-765 (2000).
13. L. W. Brady, C. Miyamoto, D. V. Woo, M. Rackover, J. Emrich, H. Bender, S. Dadparvar, Z. Steplewski, H. Koprowski and P. Black, Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 22, 225-230 (1992).
14. R. F. Meredith, M. B. Khazaeli, W. E. Plott, S. A. Spencer, R. H. Wheeler, L. W. Brady, D. V. Woo and A. F. LoBuglio, Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J. Nucl. Med. 36, 2229-2233 (1995).
15. S. Welt, A. M. Scott, C. R. Divgi, N. E. Kemeny, R. D. Finn, F. Daghighian, J. S. Germain, E. C. Richards, S. M. Larson and L. J. Old, Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol. 14, 1787-1797 (1996).
16. 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58, 972-975 (2004).
17. A. Pelegrin, A. Terskikh, D. Hayoz, Y. Chalandon, N. O. Olsson, S. Folli, F. Buchegger, B. Kromer, K. Schwarz and M. Martin, Human carcinoembryonic antigen cDNA expressed in rat carcinoma cells can function as target antigen for tumor localization of antibodies in nude rats and as rejection antigen in syngeneic rats. Int. J. Cancer 52, 110-119 (1992).
18. C. M. Haskell, F. Buchegger, M. Schreyer, S. Carrel and J-P. Mach, In vitro screening of new monoclonal anti-carcinoembryonic antigen antibodies for radioimaging human colorectal carcinomas. In Monoclonal Antibodies and Cancer (B. D. Boss, R. Langmann, I. Trowbridge and R. Dulbecco, Eds.), pp. 275-283. Academic Press, Orlando, FL, 1983.
19. S. Hammarstrom, J. E. Shively, R. J. Paxton, B. G. Beatty, A. Larson, R. Ghosh, O. Bormer, F. Buchegger, J-P. Mach and P. Burtin, Antigenic sites in carcinoembryonic antigen. Cancer Res. 49, 4852-4858 (1989).
20. G. Kohler, S. C. Howe and C. Milstein, Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur. J. Immunol. 6, 292-295 (1976).
21. C. Laurent, P. Voisin and J. P. Pouget, DNA damage in cultured skin microvascular endothelial cells exposed to gamma rays and treated by the combination pentoxifylline and alpha-tocopherol. Int. J. Radiat. Biol. 82, 309-321 (2006).
22. S. M. Goddu, R. W. Howell, L. G. Bouchet, W. E. Bolch and D. V. Rao, MIRD Cellular S Values: Self-absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Monoenergetic Electron and Alpha Particle Emitters Incorporated into Different Cell Compartments. Society of Nuclear Medicine, Reston, VA, 1997.
23. E. Pomplun, J. Booz and D. E. Charlton, A Monte Carlo simulation of Auger cascades. Radiat. Res. 111, 533-552 (1987).
24. S. M. Goddu, D. V. Rao and R. W. Howell, Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J. Nucl. Med. 35, 521-530 (1994).
25. C. E. McCulloch and S. R. Searle, Generalized, Linear, and Mixed Models. Wiley, New York, 2001.
26. N. M. Laird and J. H. Ware, Random-effects models for longitudinal data. Biometrics 38, 963-974 (1982).
27. S. Matzku, J. P. Mach, F. Buchegger, G. Moldenhauer, M. Stadler and H. Kalthoff, Detachment of cell surface-bound anticarcinoembryonic antigen immune complexes by phospholipase C. Tumour Biol. 12, 272-278 (1991).
28. P. Casalini, E. Luison, S. Menard, M. I. Colnaghi, G. Paganelli and S. Canevari, Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J. Nucl. Med. 38, 1378-1381 (1997).
29. H. Waterman and Y. Yarden, Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 490, 142-152 (2001).
30. 7Li. Mutat. Res. 632, 58-68 (2007).
31. A. Sgura, A. Antoccia, R. Cherubini, M. Dalla Vecchia, P. Tiveron, F. Degrassi and C. Tanzarella, Micronuclei, CREST-positive micronuclei and cell inactivation induced in Chinese hamster cells by radiation with different quality. Int. J. Radiat. Biol. 76, 367-374 (2000).
32. 125I decay produced lesions in chromatin. In DNA Damage by Auger Emitters (K. F. Baverstock and D. E. Charlton, Eds.). Taylor & Francis, London, 1988.
33. A. I. Kassis, Cancer therapy with Auger electrons: Are we almost there? J. Nucl. Med. 44, 1479-1481 (2003).
34. T. Alper, Effects on irradiated micro-organisms of growth in the presence of acriflavine. Nature 200, 534-536 (1963).
35. A. Haimovitz-Friedman, C. C. Kan, D. Ehleiter, R. S. Persaud, M. McLoughlin, Z. Fuks and R. N. Kolesnick, Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. Exp. Med. 180, 525-535 (1994).
36. F. Paris, Z. Fuks, A. Kang, P. Capodieci, G. Juan, D. Ehleiter, A. Haimovitz-Friedman, C. Cordon-Cardo and R. Kolesnick, Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297 (2001).
37. T. Wieder, F. Essmann, A. Prokop, K. Schmelz, K. Schulze-Osthoff, R. Beyaert, B. Dorken and P. T. Daniel, Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 97, 1378-1387 (2001).
38. E. Gulbins and R. Kolesnick, Raft ceramide in molecular medicine. Oncogene 22, 7070-7077 (2003).
39. Y. Lavie, H. Cao, S. L. Bursten, A. E. Giuliano and M. C. Cabot, Accumulation of glucosylceramides in multidrug-resistant cancer cells. J. Biol. Chem. 271, 19530-19536 (1996).
40. M. Selzner, A. Bielawska, M. A. Morse, H. A. Rudiger, D. Sindram, Y. A. Hannun and P. A. Clavien, Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 61, 1233-1240 (2001).